Direkt zum Inhalt
Merck

Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Indian journal of ophthalmology (2013-08-09)
Vinay Agrawal
ZUSAMMENFASSUNG

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
(−)-Riboflavin, from Eremothecium ashbyii, ≥98%
Supelco
Riboflavin (B2), analytical standard
Sigma-Aldrich
(−)-Riboflavin, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Supelco
(−)-Riboflavin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(−)-Riboflavin, meets USP testing specifications
USP
Riboflavin, United States Pharmacopeia (USP) Reference Standard
Riboflavin, European Pharmacopoeia (EP) Reference Standard
Riboflavin für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard